Webinars on demand

The Pathologist and Thermo Fisher Scientific are giving you the opportunity to delve into tumour mutation burden.

Cancer care has evolved over time to precise, targeted & personalized therapy options. This evolution is primarily fueled by molecular pathology, which is now under pressure from increasing tests and a shortage of pathologists.

This webinar, will discuss the benefits of next generation sequencing (NGS) for simultaneous testing of multiple biomarkers in non-small cell lung cancer.

Learn how sample preparation techniques can assist with challenges such as Phospholipid removal, sample volume limitations and throughput requirements

In 2012, cancer was the second leading cause of mortality in the world with 8.2 million cancer-related deaths.

During this webinar, Dr. Cornish will present the unique perspectives of a practicing pathologist on the emerging field of Computational Pathology and Artificial Intelligence.

Impact on KRAS/NRAS/EGFR Mutation Analysis and Personalized Cancer Treatment

The merging of three North Wales hospital pathology departments formed one of the largest labs in the country, serving a population of 700,000.

Is there a need for computational pathology in hospitals today? Are current hospital technologies ready for the change?

Tumour-specific mutations in plasma can serve as biomarkers for tumour detection, monitoring tumour response to therapies, detecting residual disease, and enabling long-term follow-up.

What can you expect from a successful protocol?

Assessment of molecular heterogeneity in tumor is a challenging task. For the first time, Palanisamy et al. have demonstrated the existence of a rare subset of prostate cancer with heterogeneous molecular aberrations involving ETS family genes and SPINK1 expression utilizing both standard immunohistochemistry (IHC) and RNA in situ hybridization (Advanced Cell Diagnostics RNAscope® Technology).